| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DOM.12099 |
| P698 | PubMed publication ID | 23551856 |
| P50 | author | Mary Ann Banerji | Q107094856 |
| Ralph A. DeFronzo | Q58689309 | ||
| P2093 | author name string | R R Henry | |
| G A Bray | |||
| S Mudaliar | |||
| R E Ratner | |||
| S R Smith | |||
| T A Buchanan | |||
| P D Reaven | |||
| D Tripathy | |||
| A E Kitabchi | |||
| N Musi | |||
| S C Clement | |||
| F B Stentz | |||
| D C Schwenke | |||
| P2860 | cites work | Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 |
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Simulated change in body fatness affects Hologic QDR 4500A whole body and central DXA bone measures | Q33255201 | ||
| Actos Now for the prevention of diabetes (ACT NOW) study | Q33488336 | ||
| Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus | Q33786881 | ||
| Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. | Q33937311 | ||
| Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach | Q34294997 | ||
| Thiazolidinediones | Q34346862 | ||
| Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). | Q34587610 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones | Q36050852 | ||
| Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes | Q36632132 | ||
| Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes | Q36805400 | ||
| Anomalies in the measurement of changes in total-body bone mineral by dual-energy X-ray absorptiometry during weight change | Q36893317 | ||
| Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial | Q36972810 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Use of thiazolidinediones and fracture risk | Q38456774 | ||
| Differential recruitment and differential regulation by physiological amines of fat cell beta-1, beta-2 and beta-3 adrenergic receptors expressed in native fat cells and in transfected cell lines | Q41471172 | ||
| PPAR-gamma: adipogenic regulator and thiazolidinedione receptor | Q41755813 | ||
| Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes | Q42999133 | ||
| Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | Q43584208 | ||
| Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients | Q43855921 | ||
| Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial | Q45161685 | ||
| Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. | Q45211541 | ||
| Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. | Q46443909 | ||
| Errors in dual-energy X-ray absorptiometry of the lumbar spine owing to fat distribution and soft tissue thickness during weight change | Q47380937 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
| Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. | Q51561183 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 931-937 | |
| P577 | publication date | 2013-05-07 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial | |
| P478 | volume | 15 |
| Q93364919 | Diabetes pharmacotherapy and effects on the musculoskeletal system |
| Q92025124 | Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health? |
| Q47223058 | Laparoscopic sleeve gastrectomy compared to a multidisciplinary weight loss program for obesity--effects on body composition and protein status |
| Q89949425 | Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use |
| Q35054970 | Minireview: nuclear receptor regulation of osteoclast and bone remodeling |
| Q38441017 | Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review |
| Q52570655 | Pioglitazone Therapy and Fractures: Systematic Review and Meta-Analysis. |
| Q37606430 | Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q38537377 | The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q34315432 | Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. |
Search more.